Pharmacognosy Basics for Understanding Herbal Drug Interactions Commonly Used for Sustained Home Remedies

Archana Dhyani

Department of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, India 248002

Abstract **:** With the goal of providing the most possible benefit to the patient, integrative medicine involves combining conventional and evidence-based alternative medications and treatments. Herb-drug interactions (HDIs) provide a significant barrier to the same. Since these HDIs may have either positive or negative effects—even be fatal—a comprehensive knowledge of HDI outcomes is crucial for the effective integration of conventional and alternative medical practises. In this article, we provide a concise overview of HDIs, highlighting the interplays between drug metabolising enzymes and transporters while discussing the many kinds of HDIs and the tools/methods for studying and predicting HDIs. Future perspectives are also discussed in this paper, with an emphasis on the endogenous participants in the interplays and methods for predicting drug-disease-herb interactions to achieve the desired results.

Keywords: Ayurveda, drug metabolizing enzymes–transporter interplays, herb–drug–disease interactions, integrative medicine

Introduction

However, the nonholistic, bug-killing, aim-based approach typical of modern medicine often results in long-term side effects (especially in the case of chronic disorders like cancer, diabetes, arthritis, etc.), making alternative approaches more appealing. Patients who have these chronic diseases often undertake combinational or multimodal treatment, sometimes without their doctors' knowledge, which might result in herb-drug interactions (HDIs). The majority of cancer patients at the MD Anderson Oncology Centre in the United States utilise herbs as part of their treatment plan (77% vs. 22%). Although, the WHO and other evaluations show that over 80% of the world's population utilises CAM for their health care requirements, and CAM has seen especially rapid growth in popularity in western nations during the previous several decades. Healthcare providers seldom inquire about the use of herbal treatments when prescribing, and patients rarely disclose their use of complementary and alternative medicine. The possibility for HDIs is a real concern when conventional and complementary and alternative medicine are used together, and this problem has arisen as a significant roadblock on the path to IM. Integrative medicine (IM) is the practise of combining different types of treatment based on evidence, such as mainstream medicine and alternative treatments.

In a nutshell, IM employs any and all treatments shown to be effective. Withania somnifera, for instance, has gained popularity as a promising new treatment option in the field of integrative cancer. The antioxidant, anti-inflammatory, immune-modulating, and antistress qualities of W somnifera aid in the fight against cancer and its repercussions. Radiation treatment and chemotherapy have both been proven to benefit from the addition of W somnifera, which boosts their efficacy while perhaps reducing their negative side effects. Asparagus racemosus as/or Tinospora

cordifolia were both acknowledged as innovative complementary therapies for integrated cancer treatment, and both Patil et al. and Borse et al. reported similar experiences.Globally, the use of IM/care for ages 18–22 is rising steadily.

The Osher Centre for Integrative Health, the Arizona Centre for Integrative Medicine, plus many more locations throughout the globe are just a few examples of the numerous venues where IM is being practised. The possible danger linked with HDIs makes integrated therapy of the illness a significantly larger issue despite the high scientific efforts underway worldwide. Since herbal medicines/CAM are becoming more popular, attention must be redirected to the possibility of drug-herb interactions. Because most herbal remedies (including single-herb preparations) include combinations of pharmacologically active ingredients, the chance of HDIs may be significantly greater than drug-drug interactions. Since these HDIs may have either positive or negative effects—even be fatal—a comprehensive knowledge of HDI outcomes is crucial for the effective integration of conventional and alternative medical practises.

In this review, we discuss HDIs in detail, including the many kinds of HDIs, how they are studied, and how they might be predicted, with an emphasis on the relationships between drug metabolising enzymes (DMEs) the transporters. It's possible for the workings of many objects to be affected by the interactions between them. Indeed, interactions between DMEs, or and transporters have the ability to modify not only the PK and PD of herbs and drugs, but also their security profile. Future perspectives are also discussed in this paper, with an emphasis on the endogenous participants in the interplays and methods for predicting drug-disease-herb interactions to achieve the desired results.

Methodology

This review was compiled using a combination of both online and traditional literature searches. We looked for studies of HDIs that emphasised the importance of interplays from 1970 and 2017 in databases such Medline, PubMed, the Cochrane the library, ResearchGate, or Google Scholar. HDI, n s-drug-metabolite interactions, drug-herb-disease-metabolite-phytochemical conversations, types, mechanism, methods and instruments, databases, new methods, integrative gets closer, regulatory guidelines or demands, mechanistic PK-PD interactions, substrate connect, protease-transporter interplays, cytokines, chemicals, and neurotransmitters interplays, and so on were among the most frequently used search terms. We found full-text articles without linguistic constraints. Previous meta-analyses and systematic reviews were also examined as were the reference lists of primary papers. There were letters sent out to professionals in the area asking for their input on certain unfinished or unpublished research. Reference lists from featured and pertinent papers were also combed through, as were abstracts from conferences and dissertations.

Explaining Herb–drug Interactions: It is now known that the administration of both conventional or herbal treatments concurrently may result in clinically significant HDIs. The HDI is frequent and may have positive, negative, or even lethal effects. In most cases, the HDI results in either desirable or unexpected outcomes. The second may progress to severe side effects, some of which can be deadly. In order to

gain the advantages and minimise the drawbacks of these interactions, a methodical strategy is necessary.

Commonly Practised Mechanisms of HDIs: Indeed, a single plant may have a wide range of physiological effects due to the complex synergistic potentially/or antagonistic effects of its many phytoconstituents, some of which are as physiologically active as and capable of influencing physiological functions as medicinal medications. Mechanisms of HDIs include pharmacodynamic and pharmacokinetic processes. Predicting pharmacokinetic interactions is far more challenging than predicting pharmacodynamic interactions. Pharmacokinetic interactions, notably those arising from functional regulation of drug-metabolizing enzymes (DMEs) such cytochromes (CYPs), drug transporters like P-gp, and protein binding, are the most often described HDIs. Drug targets may be modulated by pharmacodynamic interactions such as antagonism, addendum/summation, synergism, and so on. Multiple or complicated HDIs, on the other hand, may result in pharmacokinetic and pharmacodynamic interactions, that may or may not be mediated by interactions involving alterations to CHNET.

Absorption interactions : The predicted absorption pattern of the medicine will be altered by any herb that alters the typical gastrointestinal tract environment, leading to HDI.For instance, the rapid transit of the intestines caused by the use of any herbal stimulant or bulk-forming substance may prevent adequate absorption. Mint (Cassia senna and C angustifolia) or cascara sagrada (Rhamnus purshiana), both of which contain the active ingredient anthranoid, are two of the most widely used herbal laxatives.43,85

Furthermore, weak acidic herbal helps in extracting/formulations may not be absorbed in the presence of medications from the antacid, systemic antiulcer agent class, which would elevate the pH of stomach, or vice versa.

Distribution interactions : Drugs with a low volume of distribution (Vd) and a narrow therapeutic window (NTW) and a high affinity for plasma proteins (>95%) are more likely to interact with one another. For example, the well-known anticoagulant warfarin maintains a plasma protein binding of 98% despite having a Vd of 0.11 to 0.18 L/kg and an NTW of 1 to 2, values that shift depending on cytochrome P450 (CYP450) polymorphism. Vitamin K, some varieties of tea, and green leafy vegetables are just a few examples of substances known to interact with warfarin. It has been reported that the use of Agrimonia eupatoria reduces the effectiveness of anticoagulants. Warfarin's efficacy is increased or decreased by these agents, respectively, which might cause excessive bleeding or an increased risk of blood clots. Warfarin users must exercise extra caution while using herbs at the same time since HDIs provide a substantial danger that might prove deadly. For instance, at therapeutic dosages of ginkgo and ginger, there is little interference with the pharmacokinetics and pharmacodynamics of warfarin in healthy persons. The plasma concentration of S-warfarin is greatly decreased by echinacea. Warfarin's anticoagulant action is reduced by St. John's wort, whereas the risk of bleeding is increased by Allium sativum.

Metabolism Interactions : The term "metabolism" refers to the metabolic transformation of xenobiotics by living

organisms, often through enzyme-based elimination pathways. The length and potency of a drug's pharmaceutical impact are both affected by its metabolic rate. Many phytochemicals that make it into the bloodstream are lipophilic, making them difficult to remove; the body often converts them to hydrophilic forms via metabolism to make them more manageable. In phase I, the CYP450 isoenzyme system oxidises, reduces, or dissolves the drug/xenobiotic; in phase II, conjugation reactions like glucuronidation, acetyl and sulfation reactions increase the water solubility of the drug with a polar moiety. Many DMEs are polymorphic, and the degree to which they manifest depends on patient-related characteristics such age, gender, diagnosis, and personal preferences (PRF:SADI). Phytochemicals and xenobiotics may alter drug metabolism significantly, leading to HDIs, by affecting both hepatic or extrahepatic expression of DMEs. The US Food and Drug Administration (FDA) is aware of these concerns and has requested information about drug interactions. Different CYP enzymes play different roles in human drug metabolism. For example, CYP3A is responsible in the metabolism of around 50% of pharmaceuticals/xenobiotics, while CYP2D is responsible for about 25%, and CYP2C is responsible for about 20%.

Herbal compounds may stimulate or inhibit enzymes involved in metabolism, hence altering metabolic processes. Although it may take many days for herbal items to induce CYPs, this may result in lower drug plasma levels (due to higher drug metabolism) and diminished medication effects. When CYPs are inhibited, however, drug plasma levels might rise (due to reduced drug metabolism), heightening the medicine's impact but also increasing the risk of serious side effects. Prodrugs may have the opposite effect on induction and inhibition. CYP-mediated HDIs have been linked to a wide variety of clinically relevant adverse effects. There are a number of factors that lead to HDIs in metabolic pharmacokinetics.

Herbal constituents and drugs that are metabolised by the same CYP isoform may inhibit one another via competitive binding. Diallyl sulphide, found in garlic, is a CYP2E1 competitive inhibitor. Herbal components with electrophilic groups (such an imidazole and hydrazine group) attach to the heme part of CYPs, causing inhibition that is not competitive. For instance, piperine suppresses CYP1A and CYP2A by a mechanism that is not competitive. St. John's wort contains hyperforin, a strong noncompetitive regulator of CYP2D6. A complex between the herbal metabolite and the CYP under evaluation is responsible for the mechanism-based suppression of CYP. For instance, the suicide inhibitor of CYP2E1 is diallyl sulfone, which is formed from diallyl sulphide through an epoxide metabolite and results in the autocatalytic death of CYP2E1. Therefore, caution in taking/monitoring CYP2E1-metabolized medications while concurrently administering garlic is warranted.

Toxic effects are clearly linked to the production of reactive metabolites of drugs and xenobiotics. Herbal metabolites often cause toxicity via a combination of mechanisms, including cytotoxicity, oncogene stimulation, and hypersensitivity responses. Aristolochic acid in Aristolochia spp. is bioactivated by CYP1A1/2, leading to the formation of nitrenium ion, which in turn activates the H-ras oncogene and causes cancer. Germander (Teucrium chamaedrys), another traditional remedy, was used in the

same capacity while further acting as an antibacterial and diet adjuvant. Germander was shown to be hepatotoxic & lethal in 1991. Germander contains furan ring diterpenoids that are metabolised by CYP3A4 to produce reactive epoxide radicals. By interacting with CYP3A and epoxide hydroxylase, these epoxide radicals trigger mitochondrial permeability transition, activation of caspase 3, and hepatocyte death.

Elimination interactions

Drugs are flushed out of the body by urination, defecation, sweating, crying, sperm secretion, menstrual flow, and other bodily secretions. Proteins and enzymes known as cellular transporters play a crucial role in the detoxification of unwanted substances including drugs and xenobiotics. These include P-gp, OATP, OCTP, breast cancer resistant protein, and others. However, HDIs may occur if a plant and a medicine are taken at the same time. In addition, the diuretic properties of certain plants may interfere with the elimination of pharmaceuticals. There will be a buildup of herbs and pharmaceuticals due to the nephrotoxic drug's damaging effects on the kidneys. Renal toxicity is common with many medicines, but a drug called amphotericin B, a medication called met and tobramycin stand out as particularly harmful. Therefore, careful observation is needed to forestall the unwelcome HDIs. In addition, transporters, which regulate the entry and exit of xenobiotics from cells, need special attention in the case of elimination interactions.

Several interactions involving transporters have been discovered in recent years. Most of the transporters discovered so far are members of either the ATP-binding cassette

(also known as P-gp) or the solute carrier (SLC) super families. Substrate specific interactions between transporters and DMEs (caused by substrate overlap) may influence the performance of each. Since P-gp actively expels xenobiotics from the body, it is reasonable to assume that it serves as a detoxifying transporter and is hence largely localised in drug-eliminating organs. P-gp plays a function in effluxing chemicals back into the lumen of the intestine by being localised to the apical layer of intestinal epithelial cells, which are found in the small intestine. Both paclitaxel and digoxin have had their oral bioavailability significantly reduced by intestinal P-gp, as shown by pharmacokinetic investigations in mdr1a knockout mice. The efflux of medicines is aided by the interaction of phytochemicals with ATP-dependent protein transporters such intestinal P-gp and other multidrug-resistant proteins. Drugs that block the intestinal efflux transporter P-gp (such as quinidine, verapamil, or itraconazole) have been reported to raise plasma levels of digoxin. Inhibitors of liver transporters (eg, OATP1B1), including cyclosporine, rifampin, as well as flavonoids (a frequently encountered herbal constituent, such as quercetin as curcumin, etc), increase plasma concentrations of many -Hydroxy - methylglutaryl-CoA reductase inhibitors. To better anticipate HDIs at the vehicle level, Tucker et al.42 have explored many important factors.

In silico methods

The use of in silico approaches for investigating CYPs and their relationships with xenobiotics is on the rise. Herb-CYP interactions have also been investigated using computational methods. Simple rule-based modelling, structure-activity

connections, and quantitative three-dimensional structure-activity relationships are the three most important in silico approaches. All of them serve as valuable resources for learning about CYP responses and making informed predictions about potential metabolic HDIs, pharmacokinetic characteristics including clearance, and toxicity. The information acquired from in silico methods may have practical applications in medicine. Piperine (pentadienyl / piperidine) was studied in terms of its ability to inhibit the CYP-catalyzed reactions of arylhydrocarbon hydroxylation (CYP1A) as well as 7-methoxycoumarin-O-demethylation (CYP2) in microsomes, which prepared from unattended, 3-methylcholanthrene-treated, and phenobarbital-treated rat liver using a structure-activity relationship analysis. Based on the results of this research, it has been shown that increasing the saturation of the side chain significantly increases CYP inhibition, while modifying the phenyl or basic moieties in a few analogues results in the highest selectivity for inhibiting either obligatory or inducible CYP activities. In silico research may give preliminary clues about the potential role of CYPs in relation to HDIs, despite the fact that it is just a virtual screening method.

In vitro methods

The interactions between drugs have been studied using a variety of in vitro methods. Major models for metabolic interactions includes isolated and cultured hepatocellular or liver cell lines, cDNA-expressed enzymes, and subcellular fractions (such as hepatic microsomes, cytosols, or homogenates). Oocytes, membrane vesicle and cDNA-expressed transporters of drugs are common tools for studying transporters. So are Caco-2 or Madin-Darby canine kidney-II cells.

There are benefits and drawbacks to each of these systems. Combining these approaches, however, may provide the most precise data on the effects of herbal medications on CYPs and P-gp. Cultured male hepatocytes, for instance, provide integrity of cells for the study of enzymatic architecture and phase I/II reactions, as well as transporter studies. For rapid screening in multiwell plates, a number of CYP screening kits provide a straightforward "mix-and-read" fluorescence test. Commercial screening kits comprising recombinant cDNA-expressed enzymes from CYP are available for more than 25 human CYP enzymes. cDNA-expressed enzyme systems are utilised for in vitro screening of various chemicals linked to metabolism because of their high degree of catalytic activity, which is six times greater than that of a typical human liver microsomes sample. However, these systems were unable to examine the induction impact of test substances on CYP enzymes.

To address the shortcomings of traditional in vitro systems, such as the neglect of a crucial interaction between organ or cell types, novel techniques like IdMOC (independent discontinuous multiple organ co-culture) were created. The IdMOC system was created by Li et al. Similar to how blood flows between various organs in the human body, the IdMOC enables the coculturing cells from various parts as physically isolated cultures that are joined by an overlaying medium. As a result, medication and metabolite effects on individual organs may be assessed.

Future Perspective

Drug–disease–herb interactions: Many essential DMEs and transporters have their expression and activity modified in certain populations and/or medical states, including

children, the elderly, pregnant women, those with renal and/or hepatic impairment. It is now well acknowledged that the PK-PD may be altered in a variety of pathophy-siological circumstances.145,146 Tools and methodologies that centre on pharmacogenetic-drug interaction data from a disease perspective are necessary for comprehending drug-disease-herb interactions.199; in order to take safety and individualization in the context of drug-disease-herb interactions to the next level.200,201 However, no methods have been created or implemented to specifically address this issue. A thorough database has to be built in the near future. Such databases will be useful for minimising and rationalising the need for costly and time-consuming preclinical research into HDIs, as well as for gaining a better understanding of and making predictions about HDIs.

Novel approach to predict HDIs for integrative medicine (whole system strategy): While the scientific community has set rules for the pharmaceutical sector to follow when researching medication interactions and drug-drug interactions, no comparable guidelines exist for HDI research.202 To address all of the issues surrounding HDIs, new methods, algorithms, data bases, and/or integrated tools and methodologies need to be created. The presence of n many phytochemicals in the thyme/herbal formulations is the key challenge in producing such draught guideline for industry to comprehend the true clinical picture of HDIs.

As a result, an HDI screening should be performed on the whole herbal composition. However, one may need to learn about and/or create the bridge between allopathic and CAM drugs and formulations for predictive or clinically translational application. After that bridge is built, we'll be able to compare and contrast drugs and formulations from both conventional medicine and complementary and alternative medicine (CAM) systems like Ayurveda.

There is no way to know for sure how an extract will work or react pharmacologically only by looking at its main phytoconstituents. Several variables related to the medication, the herbal medicine, and the person determine how inhibiting or inducing DMEs and/or transporters affects pharmacokinetics in vivo. It is imperative, thus, that techniques like "Whole system strategy" be devised with the real-time clinical setting in mind. The establishment of an extensive database for forecasting and understanding HDIs in the future would not only help to save the time to effort to understand/predict HDI, it will also help to save the resources to minimize/rationalize the preliminary studies linked to HDI. In addition to this, the pharmacovigilance initiative need fresh impetus. The World Health Organisation (WHO) has expanded its pharmacovigilance programme to cover blood products, natural, medical devices, or vaccines in addition to herbals, traditional, and alternative medicines.

Conclusion

We feel that a good grasp of the risks, benefits, and/or repercussions of HDIs is crucial for getting the most out of IM and reducing the amount of suffering in the world.

References

[1] Greener M. The hidden problem of herb-drug interactions. *Prescriber.* 2016;27:22–27.

[2] Chattopadhyay P, Das KE. Practice of

Medicine (Alopathic). Kolkata: Rajendra Library; 2013.

[3] Rakel D. Integrative Medicine E-Book. Albuquerque, New Mexico: Elsevier Health Sciences; 2017.

[4] Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. *J Cancer Res Clin Oncol.* 2013;139:357–365

[5] Posadzki P, Watson LK, Alotaibi A, et al. Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys. *Clin Med (Lond).* 2013;13:126–131.

[6] Xue CC. Traditional, complementary and alternative medicine: policy and public health perspectives. *Bull World Health Organization.* 2008;86:77–78.

[7] R, Steel A, Wardle J, et al. Complementary medicine use by the Australian population: a critical mixed studies systematic review of utilisation, perceptions and factors associated with use. *BMC Complement Altern Med.* 2016;16:176.

[8] Center WM. Traditional Medicine Fact Sheet No 134, December 2008t. Available at: http://www.who.int/mediacentre/factsheets/fs134/en/. April 5, 2017

[9] Williamson EM. Drug interactions between herbal and prescription medicines. *Drug Saf.* 2003;26:1075–1092.

[10] Fugh-Berman A. Herb-drug interactions. *Lancet.* 2000;355:134–138.

[11] Wold RS, Lopez ST, Yau CL, et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. *J Am Diet Assoc* 2005; 105:54–63.

[12] Singh DP, Borse SP, Nivsarkar M. Co-administration of quercetin with pantoprazole sodium prevents NSAID-induced severe gastroenteropathic damage efficiently: evidence from a preclinical study in rats. *Exp Toxicol Pathol.* 2017;69:17–26

[13] Singh DP, Borse SP, Nivsarkar M. Overcoming the exacerbating effects of ranitidine on NSAID-induced small intestinal toxicity with quercetin: providing a complete GI solution. *Chem Biol Interact.* 2017;272:53–64.

[14] Pirotta M, Kotsirilos V, Brown J, et al. Complementary medicine in general practice: a national survey of GP attitudes and knowledge. *Aust Fam Physician.* 2010;39:946.

[15] Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. *JAMA.* 1992;268:2420.

[16] Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. *Altern Med Rev.* 2006;11:269–278

[17] Cassileth BR, Deng G. Complementary and alternative therapies for cancer. *Oncologist.* 2004;9:80–89.

[18] Abrams D, Weil A. Integrative Oncology. Oxford, United Kingdom: Oxford University Press; 2008.

[19] Borse SP, Kamble BB. Effects of Ayurvedic rasayana botanicals on CYP3A4 isoenzyme system. *J Integr Med.* 2015;13:165–172.

[20] Patil D, Gautam M, Gairola S, et al. Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy. *Integr Cancer Ther.* 2014;13:167–175.

[21] Dada Patil SJ, Bhushan, Patwardhan Botanical Drug Interactions: Case Studies From Traditional Medicines. Pune: LAP Lambert Academic Publishing; 2013.

[22] Wesa K, Gubili J, Cassileth B. Integrative oncology: complementary therapies for cancer survivors. *Hematol Oncol Clin North Am.* 2008;22:343–353.

[23] Ubale S. President of India Inaugurates Integrated Cancer Treatment and Research Centre. *J Ayurveda Integr Med.* 2011;2:97.

[24] Horrigan B, Lewis S, Abrams DI, et al. Integrative medicine in America—how integrative medicine is being practiced in clinical centers across the United States. *Glob Adv Health Med.* 2012;1:18–52.

[25] Edelman D, Oddone EZ, Liebowitz RS, et al. A multidimensional integrative medicine intervention to improve cardiovascular risk. *J Gen Intern Med.* 2006;21:728–734.

[26] Maizes V, Rakel D, Niemiec C. Integrative medicine and patient-centered care. *Explore (NY).* 2009;5:277–289.

[27] University of Maryland SoM. Cochrane CAM Field. Available at: http://www.compmed.umm.edu/cochrane.asp. April 7, 2017

[28] Belsey J, Snell T. What is evidence-based medicine? 2nd ed. *Hayward Medical Communications Publisher, United Kingdom*; 2009. Available: http://www.bandolier.org.uk/painres/download/whatis/ebm.pdf Accessed March 27, 2017.

[29] Baer HA. The work of Andrew Weil and Deepak Chopra—two holistic health/new age gurus: a critique of the holistic health/new age movements. *Med Anthropol Q.* 2003;17:233–250.

[30] Drugs.Com, Warfarin. Available: https://www.drugs.com/pro/warfarin.html Accessed February 18, 2019.